Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1

J Int AIDS Soc · 2010 · PMC3113032

Europe PMC DOI

hedged sentence

0.2770

closest p · 5.5× alpha

0.2770

boldest claim

The sentences

a nonsignificant trendP =0.277not close (p > 0.1)

There was a nonsignificant trend to more frequent emergence of new protease resistance mutations in subtype B (18%) vs. subtype C (8%, P =0.277) or non-B (7%, P =0.088) subjects; however, subtype B subjects were more likely to have previously been treated with PIs.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.